Experience the unparalleled activity of Cerba Research’s infectious diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years. Our dedicated focus spans across the spectrum, from combating the formidable challenges of COVID-19 to addressing diseases caused by HCV, HBV, HPV, influenza, CMV, RSV, hMPV, and dengue. Partnering with esteemed organizations, our state-of-the art BSL2 and BSL3 facilities ensure a secure environment for cutting-edge ID research. Get in touch to learn more. 

What Is An Infectious Disease?

The human body is endlessly dealing with intruders. Most of the time, they’re spotted and destroyed before they can do any damage. But there are times when the fight is unfair.

With increased complexity in infectious diseases (ID) protocol design, regulatory requirements, and sometimes serious public health issues, our work is cut out for us. Many viruses and bacteria still present serious health risks, such as hepatitis B (HBV), influenza, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), dengue, and more (1). We continue to focus our research per your vision, as Cerba Research provides you with a robust, adaptive ID scientific team with access to the latest science and technology.

We continue to focus our research per your vision, as Cerba Research provides you with a robust, adaptive ID scientific team with access to the latest science and technology. As such, Cerba Research can provide a wide range of integrated specialty and safety testing to your existing central laboratory processes. Cerba Research NL (The Netherlands) can serve as a central and reference virology laboratory for your pre-clinical / phase I-IV clinical trials.  Get in touch to learn more.

Cerba Research ID And Vaccines Services

There are often significant challenges to ID drug research and development, and complex clinical trials require a laboratory partner who provides services throughout the development spectrum. Cerba Research understands these difficulties and can provide you with assay innovation, customized protocols, and the introduction of new tools for your ID trial.

Our team is experienced in many innovative techniques. In fact, we have a global network of laboratories that offers a wide range of capabilities, ranging from safety testing (also known as routine testing) to best-in-class molecular assays (qPCR, ddPCR, NGS, long-read sequencing), whole exome sequencing, whole genome sequencing, microbiome, immune repertoire sequencing, immunohistochemistry (IHC) and virological assays (phenotyping, viral culture, ELISpot / flurospot, ELISA, high-throughput plaque reduction assays, ViroSpot™), flow cytometry, and more. We also facilitate state-of-the-art technologies, subject matter expertise, specialized logistics, and operations to accelerate your ID research and development.

Remember that if we don’t have it, we can customize it. Thanks to our expertise in assay development, validation (2), customization capabilities, tech transfers, robust kit building, sample management, and logistics, we deliver shipments on time 99% of the time. Get in touch to learn more.

We Perform Specialty Testing In ~90% Of Our ID Portfolio

We have had ~600 ID projects since 2018, including ~250 COVID-19 trials. We perform specialty testing in 90%+ of those trials. Specifically, we can perform genomics, cell-based neutralizing assays, virus inhibition titration, microbiome and bacterial whole genome sequencing, flow cytometry, and more. We can also perform any routine testing (aka safety testing), such as, but not limited to, coagulation, biochemistry, urinalysis, pregnancy test, COVID testing and serology, which are essential for any ID trial. Our high-resolution viral plaque assays enable studies on inhibiting both single and multiple infection / replication cycles. Furthermore, our dedicated research & development specialists offer novel, custom-designed assays and expert advice on assay.

A Cerba Research Unique Offering For Your Next Generation ID Trial

References

1. World Health Organization: Fact sheets. URL [https://www.who.int/news-room/fact-sheets]

2. Selliah N, Nash V, Eck S, Green C, Oldaker T, Stewart J, Vitaliti A, Litwin V. Flow Cytometry Method Validation Protocols. Curr Protoc. 2023 Aug;3(8):e868. doi: 10.1002/cpz1.868. Erratum in: Curr Protoc. 2024 Jan;4(1):e988. PMID: 37606503.